Pregnancy outcomes in patients treated with bosutinib

por Cortes, Jorge E, Gambacorti-Passerini, Carlo, Deininger, Michael, Abruzzese, Elisabetta, DeAnnuntis, Liza, Brümmendorf, Tim H
Publicado 2020

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study

por Gambacorti-Passerini, Carlo, Cortes, Jorge E., Lipton, Jeff H., Kantarjian, Hagop M., Kim, Dong-Wook, Schafhausen, Philippe, Crescenzo, Rocco, Bardy-Bouxin, Nathalie, Shapiro, Mark, Noonan, Kay, Leip, Eric, DeAnnuntis, Liza, Brümmendorf, Tim H., Khoury, H. Jean
Publicado 2018

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

por Hurvitz, Sara A., Gonçalves, Anthony, Rugo, Hope S., Lee, Kyung‐Hun, Fehrenbacher, Louis, Mina, Lida A., Diab, Sami, Blum, Joanne L., Chakrabarti, Jayeta, Elmeliegy, Mohamed, DeAnnuntis, Liza, Gauthier, Eric, Czibere, Akos, Tudor, Iulia Cristina, Quek, Ruben G.W., Litton, Jennifer K., Ettl, Johannes
Publicado 2019

Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses

por Mehra, Niven, Fizazi, Karim, de Bono, Johann S, Barthélémy, Philippe, Dorff, Tanya, Stirling, Adam, Machiels, Jean-Pascal, Bimbatti, Davide, Kilari, Deepak, Dumez, Herlinde, Buttigliero, Consuelo, van Oort, Inge M, Castro, Elena, Chen, Hsiang-Chun, Di Santo, Nicola, DeAnnuntis, Liza, Healy, Cynthia G, Scagliotti, Giorgio V
Publicado 2022